---
figid: PMC9146021__ijms-23-05544-g008
pmcid: PMC9146021
image_filename: ijms-23-05544-g008.jpg
figure_link: /pmc/articles/PMC9146021/figure/ijms-23-05544-f008/
number: Figure 8
figure_title: ''
caption: Down-regulation of HSD17B13 in the liver improves lipid metabolisms in HFD-fed
  mice. (Aâ€“C) Alterations of hepatic lipid classes in the liver of HFD-fed mice injected
  with AAV8-shHsd17b13. (D) Volcano plot of differential lipid metabolisms. (E) Heatmaps
  of the expression of significant lipid class. (F) KEGG pathway. HFD, high fat diet;
  MG, monoglyceride; DG, diacylglycerol; TG, triacylglycerol; LPC, lysophosphatidylcholine;
  LPE, lysophosphatidyl ethanolamine; LPG, lysophosphatidylglycerol; LPI, lysophosphatidyl
  inositol; LPS, lysophosphatidylserine; PA, phosphatidic acid; PC, phosphatidylcholine;
  PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol;
  PS, phosphatidylserine; FA, free fatty acid; CE, cholesteryl ester; Cer, ceramide;
  SM, sphingomyeline.
article_title: Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase
  13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.
citation: Meixi Wang, et al. Int J Mol Sci. 2022 May;23(10):5544.
year: '2022'

doi: 10.3390/ijms23105544
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI

keywords:
- 17-beta-hydroxysteroid dehydrogenase type 13
- non-alcoholic fatty liver disease
- steatosis
- fibrogenesis
- drug target

---
